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Di(2-ethylhexyl)phthalate (DEHP) is a widely used plasticizer and a potentially nongenotoxic carcinogen. Its mechanism had
been earlier proposed based on peroxisome proliferator-activated receptor α (PPARα) because metabolites of DEHP are agonists.
However, recent evidence also suggests the involvement of non-PPARα multiple pathway in DEHP-induced carcinogenesis. Since
there are diﬀerences in the function and constitutive expression of PPARα among rodents and humans, species diﬀerences are
also thought to exist in the carcinogenesis. However, species diﬀerences were also seen in the lipase activity involved in the ﬁrst
step of the DEHP metabolism, which should be considered in DEHP-induced carcinogenesis. Taken together, it is very diﬃcult
to extrapolate the results from rodents to humans in the case of DEHP carcinogenicity. However, PPARα-null mice or mice
with human PPARα gene have been developed, which may lend support to make such a diﬃcult extrapolation. Overall, further
mechanical study on DEHP-induced carcinogenicity is warranted using these mice.
Copyright © 2008 Y. Ito and T. Nakajima. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Di(2-ethylhexyl)phthalate (DEHP) a plasticizer around the
world, suggesting that many people come across this chem-
ical every day. Animal studies showed that this chemical is a
nongenotoxic carcinogen. Metabolites of DEHP, mono- and
dicarboxylic acids, transactivate peroxizome proliferator-
activated receptor α (PPARα), which has been thought
to result in nongenotoxic carcinogenesis [1, 2]. However,
the latest studies also showed the involvement of non-
PPARα pathways; multiple pathways might be involved in
the pathway of DEHP-induced carcinogenicity [3]. There are
speciesdiﬀerencesinthefunctionalactivationorconstitutive
expression of rodent and human PPARα, and that in humans
is thought to be less active and expressive than those of
rodents. Recently, inﬂammation-related carcinogenesis has
drawn attention [4, 5]. PPARα is involved not only in the
induction of target genes such as β-oxidation enzymes of
fatty acids but also in anti-inﬂammation signaling [6, 7],
suggesting that PPARα also may protect against carcinogene-
sis.Speciesdiﬀerencesinlipase activity(DEHP-metabolizing
enzyme) among mice, rats, and marmosets have been also
reported recently [8], suggesting that this kinetic diﬀerence
should be considered in the species diﬀerences in DEHP-
induced carcinogenesis. In this review, we focused on
DEHP-induced hepatic carcinogenesis in relation to PPARα-
dependentandPPARα-independentpathways,anddiscussed
the science policy.
2. PPARs
PPARs are involved in a member of the nuclear hormone
receptor superfamily, and consist of three subunits: PPARα,
PPARβ/δ,a n dP P A R γ [9]. These three isoforms have been
identiﬁed at the organ-speciﬁc level. In the respective organ,
PPARs function as transcription factors through the classic
ligand-dependent nuclear hormone receptor mechanism.
Upon binding to their ligands, PPARs undergo confor-
mational changes that allow corepressor release [10]. The
PPAR-ligand complex binds to direct repeat 1 elements or
peroxisome proliferator response elements (PPREs), usually
located upstream of the target genes, which results in the
induction of fatty acid transport and metabolism, glucose
metabolism, and also elicitation of anti-inﬂammatory eﬀects
[6, 11].
As one of the three isoforms, PPARα is mainly expressed
in organs that are critical in fatty acid catabolism, such as
liver, heart, and kidney [7]. Thus, this nuclear receptor is2 PPAR Research
primarilyinvolvedintheregulationoffattyacidmetabolism.
In addition to this function, PPARα also has various
functions including the promotion of gluconeogenesis, lipo-
genesis, ketogenesis, and anti-inﬂammatory eﬀects [6].
3. PPARα LIGANDS
The ligands of PPARα represent a diverse group of chemicals
including not only endogenous ligands but also exogenous
synthetic ligands with a high likelihood of clinical, occupa-
tional, and environmental exposure of humans to chemicals
[1, 12]. The primary endogenous ligands are fatty acids,
mainly the 18–20 carbon polyunsaturated fatty acids and
eicosanoids [7, 13–17]. As exogenous ligands, ﬁbrates and
thiazolidinediones are involved. Additionally, the general
population is exposed to environmental chemicals such as
plasticizers (e.g., phthalates), solvents (e.g., tetrachloroethy-
lene and trichloroethylene), perﬂuorooctanoic acid and
herbicides (e.g., 2, 4-dichlorophenoxyacetic acid, diclofop-
methyl, haloxyfop, lactofen, and oxidiazon).
Of these ligands, the toxicity of DEHP is well established
in relation to PPARα. This chemical is used as a plasticizer
to improve the plasticity and elasticity of polyvinyl chloride
products that have become ubiquitous in our daily living.
These products are widely used in building materials,
wallpaper and ﬂooring, wire covering, vinyl sheeting for
agriculture, food packages, and medical devices such as
intravenous and hemodialysis tubing and blood bags. The
recent production of DEHP in Japan has approached 14000
tonsperyear,whichaccountsforabout54%ofallplasticizers
used [11]. It is noted that mono- and dicarboxylic acid
metabolites of DEHP, not DEHP itself, act as ligands for
PPARα [18] and have potentially adverse eﬀects on liver, kid-
ney, heart, and reproductive organs though monocarboxylic
acid, mono(2-ethylhexyl) phthalate (MEHP), also binds to
PPARγ [18].
4. SPECIES DIFFERENCES IN PPARα
Since there are species diﬀerences in the toxicity of PPARα
agonists,theexpressionlevelsorfunctionsofthereceptorare
thought to be diﬀerent among species. Several explanations
for the species diﬀerences in response to the ligands have
been suggested [19, 20]. One of the major factors was
considered to be due to diﬀerences in the levels of PPARα
expression [21, 22] although other possibilities include
diﬀerences in ligand aﬃnity between rodent and human
PPARα,d i ﬀerences in cellular context of PPARα expression,
and those in PPRE sequences found upstream of critical
targetgenes[23,24].Indeed,PPARαexpressioninhumansis
about 1/10 times less than that in rodents [25]. In addition,
micro-RNAexpressionregulatedbyPPARαhasbeenrecently
reported to be changed in wild-type mice, but not in
mice with human PPARα gene [26]; Wy-14,643 inhibited
a micro-RNA let-7C which is involved in suppression of
tumorigenesis in wild-type mice, but neither in PPARα-null
micenorinmicewithhumanPPARαgene.Micewithhuman
PPARα gene are resistant to hepatocellular proliferation
thoughtheyrespondtoWy-14,643inβ-oxidationandserum
triglycerides [27]. These results suggest that the function of
the PPARα signaling in liver proliferation and tumorigenesis
by the chemical exposure is not always similar in mice and
humans.
In regard to the species diﬀerences in the PPREs, the
lack of acyl CoA oxidase (ACO) induction in studies on liver
biopsies from humans treated with hypolipidemic drugs or
primary human hepatocytes treated with Wy-14,643 may
be attributable to an inactive functional PPRE since the
sequence of a PPRE for the ACO gene from a small number
of human liver biopsy samples was found to be diﬀerent
from that of the rats [28]. However, Reddy remarked at a
panel discussion that, although the sequence of ACO gene
promoterinthemousewasalsodiﬀerentfromthatintherat,
bothrodentsareresponsivetosomeperoxisomeproliferators
in ACO induction [20]. In addition, diﬀerences in the ability
of rodents and human PPAR to recognize and bind PPRE
are unlikely since the DNA binding domains of the human
and rodent PPARα are 100% homologous [29, 30]. Though
characterized from only a limited number of individuals, the
prevalenceinthepopulationofdefectivePPARallelescannot
bedeterminedatthispoint[31].Thespeciesdiﬀerenceinthe
sequence of PPRE may not be involved in the diﬀerence in
response to ligands between rodents and humans.
In addition to the lower expression levels of PPARα in
human, there was a truncated, inactive form of PPARα in
human liver, suggesting that the expression of full-length
functional PPARα was very low. These inactive forms of
PPARαmaybeinsuﬃcienttobindPPREbecausePPREsmay
be occupied in vivo by other nuclear receptors that bind to
similar sequences, thus aﬀecting responsiveness to ligands
[25].
5. SPECIES DIFFERENCES IN DEHP METABOLISM
In addition to the species diﬀerences in PPARα func-
tions or expression levels, we should also be mindful of
the importance of those in the metabolism of DEHP
between rodents and humans. DEHP absorbed in the body
is ﬁrst metabolized by the catalytic action of lipase to
produce MEHP and 2-ethylhexanol (2-EH) [32]. Some
MEHP is then conjugated with UDP-glucuronide by UDP-
glucuronosyltransferase (UGT) and excreted in the urine.
The remaining MEHP is excreted directly in the urine or
is oxidized by cytochrome P450 4A, then further oxidized
byalcoholdehydrogenase(ADH)oraldehydedehydrogenase
(ALDH)todicarboxylicacidorketones.2-EHismetabolized
mainly to carboxylic acid (mainly 2-ethylhexanoic acid
(2HEA)) via 2-ethylhexanal by catalytic action of ADH and
ALDH. Thus, lipase may be an essential enzyme to regulate
the DEHP metabolism; knowing the species diﬀerence in the
lipase activity may be an important tool to clarify the species
diﬀerence in metabolism.
Recently, the activities of lipase, UGT, ADH, and ALDH
for DEHP metabolism in several organs were measured and
compared among mice, rats, and marmosets [8]. Marmosets
were used as a reference to human. Clear-cut species
diﬀerences were seen in the activities of the four enzymes
involved in the DEHP metabolism among mice, rats, andY. Ito and T. Nakajima 3
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Figure 1: Species diﬀerences in lipase activities (pmol/mg protein
in microsomal fragment/min) using hepatic microsomes in liver,
small intestine, kidney, and lung from mice, rats, and marmosets.
Lipase activity was measured by GC/MS. Substrate concentration
(DEHP) used was 1mM. Each white bar (6 mice), grey bar (5
rats), or black bar (5 marmosets) represents the mean ± standard
deviations. Lipase activity was not detected in marmoset lung
(under 1pmol/mg protein/min). Comparisons were made using
analysis of variance and the Tukey-Kramer HSD post hoc test.
A logarithmic transformation was applied to lipase activities in
microsome samples from the small intestine and kidneys before
Tukey-Kramer analysis. Diﬀe r e n tl e t t e r s( a ,b ,c )o nt h et o po fe a c h
bar in each organ indicate that they are signiﬁcantly diﬀerent from
each other (P < .05).
marmosets. The most prominent diﬀerence was observed in
the lipase activity with an almost 148- to 357-fold diﬀerence
between the highest activity in mice and the lowest in
marmosets (Figure 1). These diﬀerences were comparable to
those in the kinetic parameter, Vmax. These results suggest
that the constitutive levels of lipase were greater in the mice
and rats than in marmosets. Indeed, lipase-mRNA levels
in livers from mice or rats were much higher than those
in marmoset (Figure 2). Thus, concentrations of MEHPs
(ligands to PPARα) in the body were higher in mice or
rats than in marmosets when the same dose of DEHP was
administered [33].
Besides species diﬀerences in the constitutive levels of
lipase, Km values of DEHP for lipase of marmosets were
much higher than in rats or mice, suggesting the species
diﬀerences in the DEHP aﬃnity for lipase; the aﬃnity of
DEHP for lipase in the marmosets may be lower than that
of mice or rats. The aﬃn i t yi nh u m a nm a yb ee v e nl o w e r
than that in primates; cumulative 14C excretion in urine
of African green monkey following bolus injection of 14C-
DEHP leached into autologous plasma occurred earlier than
in human [34].
6. MECHANISM OF DEHP-INDUCED CANCER
DEHP causes tumors, especially in liver when chronically
administered to rats and mice [35–39], similar to the other
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Figure 2: Lipase-mRNA levels in mice, rats, and marmosets. Each
mRNA level was measured by real-time quantitative PCR and
normalized to the GAPDH-mRNA level in the same preparation.
Mouse liver mean was assigned a value of 100. Figures represent
mean±SD from 6 from mice and 5 from rats and marmosets.
Comparisons were made using analysis of variance and the Tukey-
Kramer HSD post hoc test. Diﬀerent letters (a, b, c) on the top of
each bar in each organ indicate that they are signiﬁcantly diﬀerent
from each other (P < .05).
peroxisome proliferators such as Wy-14643. Table 1 shows
that DEHP induces hepatic tumors in mice and rats. From
the viewpoint of percentage in feed, the lowest-observed
eﬀect-level (LOEL) of DEHP carcinogenicity in the rat was
0.6%,andtheno-observedeﬀect-level(NOEL)was0.1%[2].
In the mouse, the corresponding values may be 0.05% for
LOEL and 0.01% for NOEL because the study in which male
mice were exposed to 0.05% DEHP for 78 weeks exhibited
a signiﬁcant increase in the hepatic tumor incidence rate
compared with controls, but not when exposed to 0.01%
DEHP [40].
DEHP also has potential for carcinogenesis in other
organs; pancreatic acinar cell adenoma and mononuclear
cell leukemia incidences were signiﬁcantly increased in male
F344 rat but not in F344 female rat and B6C3F1 mouse of
both sexes after DEHP exposure [35, 36, 44]. The reason why
these cancers are not observed in female rat has not been
identiﬁed.
Chronic treatment with PPARα agonist results in an
increased incidence of liver tumors which were thought to
have occurred through a PPARα-mediated mechanism as
revealed by the resistance of PPARα-null mice to liver cancer
induced by Wy-14,643 exposure for 11 months [46]. All the
wild-type mice fed with 0.1% Wy-14643 diet for 11 months
had multiple hepatocellular neoplasms, including adenomas
and carcinomas, while thePPARα-null mice fed with the
0.1% Wy-14643 diet for the same duration were unaﬀected.
Ward et al. [47] reported that exposure for only six months
to 12000ppm DEHP caused induction of peroxisomal
enzymes, liver enlargement, and histopathological increases
in eosinophil counts and peroxisomes in the cytoplasm of
wild-type mice, while there were no such toxic ﬁndings
in the liver of PPARα-null mice. Thus, DEHP-derived4 PPAR Research
Table 1: Primary studies on DEHP-induced carcinogenesis in mice and rats (modifying the paper reported by Huber et al. [2]).
Author Sex Route Duration Dosage Type of tumor Tumor frequency (%)
Species, strain
[39] Rat F344 M Feed 103w 0.00% Hepatic tumors 6
0.60% 12
1.20% 24
F Feed 103w 0.00% Hepatic tumors 0
0.60% 12
1.20% 26
[41] Rat F344 F Feed 2y 0.00% Hepatic tumors 0
0.03% 6
0.10% 5
1.20% 30
[42] Rat F344 MO r a l 2 4 m 0 ( w a t e r )Liver carcinoma 4
0 (vehicle) 12
2EH 50mg/kg 6
2EH 150 6
2EH 500 2
MO r a l 2 4 m 0 ( w a t e r )Liver adenoma 0
0 (vehicle) 0
2EH 50mg/kg 0
2EH 150 2
2EH 500 0
FO r a l 2 4 m 0 ( w a t e r )Liver carcinoma 0
0 (vehicle) 2
2EH 50mg/kg 2
2EH 150 4
2EH 500 0
[42] Mouse B6C3F1 MO r a l 1 8 m 0 ( w a t e r )Liver carcinoma 8
0 (vehicle) 12
2EH 50mg/kg 12
2EH 200 14
2EH 750 18
MO r a l 1 8 m 0 ( w a t e r )Liver adenoma 0
0 (vehicle) 0
2EH 50mg/kg 0
2EH 200 0
2EH 750 2
FO r a l 1 8 m 0 ( w a t e r )Liver carcinoma 2
0 (vehicle) 0
2EH 50mg/kg 2
2EH 200 6
2EH 750 10
[43] Rat F344 M Feed 2y 0ppm Hepatocellular carcinoma 2
6000ppm 2
12000ppm 10
M Feed 2y 0ppm Hepatocellular neoplastic
nodule
4
6000ppm 10
12000ppm 14Y. Ito and T. Nakajima 5
Table 1: Continued.
Author Sex Route Duration Dosage Type of tumor Tumor frequency (%)
Species, strain
F Feed 2y 0ppm Hepatocellular carcinoma 0
6000ppm 4
12000ppm 16
0ppm Hepatocellular neoplastic
nodule
0
6000ppm 8
12000ppm 10
[43] Mouse B6C3F1 M Feed 2y 0ppm Hepatocellular carcinoma 18
3000ppm 29
6000ppm 38
0ppm Hepatocellular adenoma 10
3000ppm 23
6000ppm 20
F Feed 2y 0ppm Hepatocellular carcinoma 0
3000ppm 14
6000ppm 34
0ppm Hepatocellular adenoma 2
3000ppm 10
6000ppm 2
[40] Rat F344 M Diet 79w 0ppm Hepatocellular carcinoma 10
2500ppm 0
12500ppm 40
0ppm Hepatocellular adenoma 10
2500ppm 10
12500ppm 10
F Diet 79w 0ppm Hepatocellular carcinoma 0
2500ppm 0
12500ppm 20
0ppm Hepatocellular adenoma 0
2500ppm 0
12500ppm 10
M Diet 105w 0ppm Hepatocellular carcinoma 1
100ppm 0
500ppm 2
2500ppm 5
12500ppm 30
Recovery 13
0ppm Hepatocellular adenoma 5
100ppm 10
500ppm 5
2500ppm 12
12500ppm 26
Recovery 22
0ppm Hepatocellular carcinoma 0
100ppm 2
500ppm 0
2500ppm 2
12500ppm 18
Recovery 76 PPAR Research
Table 1: Continued.
Author Sex Route Duration Dosage Type of tumor Tumor frequency (%)
Species, strain
F Diet 105w 0ppm Hepatocellular adenoma 0
100ppm 6
500ppm 2
2500ppm 3
12500ppm 10
[40] Mouse B6C3F1 M Diet 79w 0ppm Hepatocellular carcinoma 0
100ppm 0
500ppm 10
1500ppm 0
6000ppm 7
0ppm Hepatocellular adenoma 7
100ppm 10
500ppm 20
1500ppm 10
6000ppm 7
F Diet 79w 0ppm Hepatocellular carcinoma 0
100ppm 0
500ppm 0
1500ppm 0
6000ppm 13
0ppm Hepatocellular adenoma 0
100ppm 10
500ppm 10
1500ppm 10
6000ppm 27
M Diet 105w 0ppm Hepatocellular carcinoma 6
100ppm 8
500ppm 14
1500ppm 22
6000ppm 31
Recovery 22
0ppm Hepatocellular adenoma 6
100ppm 17
500ppm 20
1500ppm 22
6000ppm 27
Recovery 5
F Diet 105w 0ppm Hepatocellular carcinoma 4
100ppm 3
500ppm 5
1500ppm 15
6000ppm 23
Recovery 42
0ppm Hepatocellular adenoma 0
100ppm 3
500ppm 6
1500ppm 14
6000ppm 49
Recovery 24Y. Ito and T. Nakajima 7
Table 1: Continued.
Author Sex Route Duration Dosage Type of tumor Tumor frequency (%)
Species, strain
[43] Rat F344 M Feed 2y 0, 6000,
12000ppm
Pituitary adenoma
or carcinoma
Decrease in highest dose
F Feed 2y 0, 6000,
12000ppm
Pituitary adenoma
or carcinoma
Decrease in lower dose
M Feed 2y 0, 6000,
12000ppm
T h y r o i dC - c e l la d e n o m a
or carcinoma
Decrease in highest dose (unclear)
M Feed 2y 0, 6000,
12000ppm
Testis interstitial cells
tumor
Decrease in highest dose
F Feed 2y 0, 6000,
12000ppm Mammary gland Decrease in highest dose
[36] Rat F344 MD i e t 7 8 w0ppm Interstitial cells tumor or
testes
90
2500ppm 100
12500ppm 30
M Diet 104w 0ppm Interstitial cells tumor or
testes
92
100ppm 90
500ppm 91
2500ppm 92
12500ppm 31
0ppm Mononuclear cell leukemia 23
100ppm 26
500ppm 29
2500ppm 49
12500ppm 42
0ppm Pancreatic acinar cell
adenoma
0
100ppm 0
500ppm 0
2500ppm 0
12500ppm 8
F Diet 104w 0ppm Mononuclear cell leukemia 22
100ppm 34
500ppm 20
2500ppm 25
12500ppm 26
0ppm Pancreatic acinar cell
adenoma
0
100ppm 0
500ppm 0
2500ppm 0
12500ppm 3
[44] Rat F344 MD i e t 7 9 w0ppm Interstitial cells tumor or
testes
90
12500ppm 30
0ppm Mononuclear cell leukemia 0
12500ppm 108 PPAR Research
Table 1: Continued.
Author Sex Route Duration Dosage Type of tumor Tumor frequency (%)
Species, strain
M Diet 105w 0ppm Interstitial cells tumor or
testes
92
12500ppm 31
Recovery 32
0ppm Mononuclear cell leukemia 23
12500ppm 42
Recovery 53
[35] Mouse B6C3F1 M, Diet 78w, 0, 100, 500, 1500, No data about tumors
6000ppm
[44] Rat F344 F Diet 79w 0ppm, 12500ppm No data about tumors
[44] Mouse B6C3F1 M, Diet 79w 0ppm, 6000ppm, No data about tumors
M, Diet 105w 0ppm, 6000ppm, No data about tumors
[45] Mouse 129/Sv, PPARα-
null
MD i e t 2 1 m Liver tumors
(hepatocellular adenoma,
hepatocellular carcinoma,
cholangiocellular
carcinoma)
Wild-type PPARα-null
0% 0 4
0.01% 9 4
0.05% 10 25.8
carcinogenicity was thought to be mediated by PPARα,
similar to Wy-14,643, and DEHP was considered to cause
primarily PPARα-dependent carcinogenicity in rodents, but
it is considered to be relatively safe in humans, similar
to other ligands [2]. However, Ward et al. [47] could not
directly observe DEHP-derived tumors in the wild-type
mice, because exposure to DEHP for 6 months may not
be suﬃcient to induce hepatic tumors, as suggested by
Marsman et al. [48]; they reported that DEHP tumorigenesis
required longer exposure periods than Wy-14,643. It is
doubtful whether DEHP deﬁnitively induces hepatic tumors
via PPARα.
As mentioned above, the following simple mechanism
has been proposed for the DEHP-induced hepatocarcino-
genesis; when DEHP was administered to rats and mice,
the chemical caused an increase in cell proliferation and
peroxisome proliferation [49]. The latter is accompanied by
an increase in both peroxisomal and mitochondrial fatty
acid metabolizing enzymes such as ACO. As a byproduct
of fatty acid oxidation, enzymes involved with β-oxidation
generate H2O2, resulting in elevated oxidative stress. DEHP
also causes an increase in proinﬂammatory cytokines and
inhibition of apoptosis [2, 24].
DEHP-induced liver carcinogenesis in rodents, however,
appears to involve more complex pathways as described in
the following events whereby various combinations of the
molecular signals and multiple pathways may be involved
[3]. DEHP is metabolized to bioactive metabolites which are
absorbed and distributed throughout the body; they might
induce PPARα-independent activation of macrophages and
production of oxidants, and also activate PPARα and
sustained induction of target genes. The inductions lead
to enlargement of hepatocellular organelles, an increase
in cell proliferation, a decrease in apoptosis, sustained
hepatomegaly, chronic low-level oxidative stress and accu-
mulation of DNA damage, and selective clonal expansion
of the initiated cells. Finally, preneoplastic nodules might be
induced and might result in adenomas and carcinoma.
Peraza et al. [10] also suggest that PPARα is the only
receptor in PPARs that is known to mediate carcinogenesis,
while the prevailing evidence suggests that PPARβ,P P A R γ,
and their ligands appear to be tumor modiﬁers that inhibit
carcinogenesis, albeit there is still controversy in the ﬁeld.
Melnick [50] also addressed non-PPARα mechanisms for
DEHP-induced carcinogenicity as follows. (1) Peroxisome
proliferator-induced tumorigenesis is related to the genes
involved in cellular proliferations of, for example, p38
mitogen-activated protein kinase, which is not involved
in peroxisome proliferations [51]. (2) DEHP and other
peroxisome proliferators stimulated growth regulatory path-
ways such as immediate early genes for carcinogenesis (c-
jun, c-fos, junB, egr-1), mitogen-activated protein kinase,
extracellular signal-regulated kinase, and phosphorylation of
p38, which were dissociated from PPARα activation in rat
primary cultures [52–54]. These ﬁndings also support the
view that peroxisome proliferators, including DEHP, may
have the potential for tumorigenesis via non-PPARα signal
pathways.
In recent years, an inﬂammation-associated model of
cancers has been given attention [4, 5]. PPARα exerts anti-
inﬂammation eﬀects by repressing nuclear factor kappa B
(NFκB) [55], which inhibits inﬂammation signaling and
subsequent cancer [4].
Ito et al. [45] proposed possibility of DEHP tumorigene-
sis via a non-PPARα pathway using PPARα-null mice. They
compared DEHP-induced tumorigenesis in wild-type andY. Ito and T. Nakajima 9
PPARα-nullmicetreatedfor22monthswithdietscontaining
0, 0.01, or 0.05% DEHP. Surprisingly, the incidence of liver
tumors was higher in PPARα-null mice exposed to 0.05%
DEHP (25.8%) than in similarly exposed wild-type mice
(10%), while the incidence was 0% in wild-type miceand
4% in PPARα-null mice without DEHP exposure. The levels
of 8-hydroxydeoxyguanosine increased dose-dependently in
miceofbothgenotypes,butthedegreeofincreasewashigher
in PPARα-null mice than in wild-type mice. NFκBl e v e l s
also signiﬁcantly increased in a dose-dependent manner in
PPARα-null mice. The proto-oncogene c-jun-mRNA was
induced, while c-fos-mRNA tended to be induced only in
PPARα-null mice fed with 0.05% DEHP-containing diet.
These results suggest that chronic low-level oxidative stress
induced by DEHP exposure may lead to the induction of
inﬂammation and/or the expression of proto-oncogenes,
resulting in a high incidence of tumorigenesis in PPARα-
null mice. Moderate activated PPARα might protect from
p65/p50 NFκB inﬂammatory pathway caused by chronic
DEHP exposure in wild-type mice. Although cross-talk of
PPARγ,b u tn o tP P A R α, with cyclooxygenase 2 (Cox-2),
which also was related with inﬂammation-induced hepa-
tocellular carcinoma, has been suggested [56], there was
neither induction of Cox-2 nor PPARγ in both genotyped
mice of that study (data not shown).
Additionally, we compared the mechanisms of tumori-
genesis between wild-type mice and PPARα-null mice using
hepatocellularadenomatissuesofbothgenotypedmice[57].
The microarray proﬁles showed that the up- or downreg-
ulated genes were quite diﬀerent between hepatocellular
adenoma tissues of wild-type mice and PPARα-null mice
exposed to DEHP, suggesting that their tumorigenesis mech-
anisms might be diﬀerent. Interestingly, the gene expressions
of apoptotic peptidase activating factor 1 and DNA-damage-
inducible 45α (Gadd45α) were increased in the hepatocel-
lular adenoma tissues of wild-type mice exposed to DEHP,
whereas they were unchanged in corresponding tissues
of PPARα-null mice. On the other hand, the expressions
of cyclin B2 and myeloid cell leukemia sequence 1 were
increased only in the hepatocellular adenoma tissues of
PPARα-null mice. Taken together, DEHP may induce hepa-
tocellular adenomas, partly via suppression of G2/M arrest
regulated by Gadd45α and caspase 3-dependent apoptosis
in PPARα-null mice. However, these genes may not be
involved in tumorigenesis in wild-type mice. In contrast,
the expression level of Met was notably increased in the
liver adenoma tissue of wild-type mice, which may suggest
the involvement of Met in DEHP-induced tumorigenesis in
wild-type mice. However, we could not determine whether
DEHPpromotedthespontaneouslivertumorinPPARα-null
mice because spontaneous hepatocellular tumors are known
to occur in these mice at 24 months of age [58], while we
observed DEHP-induced tumorigenesis at 22 months of age.
To clarify this, gene expression proﬁles of liver tumors in the
control group must be analyzed.
Taken together, the mechanisms of DEHP-induced car-
cinogenesis do not consist of only a simple pathway such
as PPARα-mediated peroxisome proliferation as mentioned
by Rusyn et al. [3]. PPARα-independent pathways may
also exist and, by contrast, activated PPARα may protect
against DEHP-induced carcinogenesis. The valance of the
production of oxidative stress via the transactivation of
PPARα and subsequent DNA damages versus the eﬀective
exertion of anti-inﬂammation by activating the receptor may
determine the incidence of DEHP-induced tumors.
7. FUTURE INVESTIGATIONS
To determine the mechanism of species diﬀerence in
response to peroxisome proliferators, a mouse line with
human PPARα was produced and designated hPPARαTetOﬀ
[27]. This mouse line expresses the human receptor in
liver in a PPARα-null background by placing the hPPARα
cDNA under control of the Tet-Oﬀ system of doxycycline
control with the liver-speciﬁc LAP1 (C/EBPβ)p r o m o t e r .
Interestingly, the hPPARαTetOﬀ mice express the human
PPARα protein at levels comparable to those expressed in
wild-type mice; so we should not need to consider the
species diﬀerences in the expression of PPARα between mice
and humans. Treatment of this mouse line with Wy-14,643
revealed induction of genes’ encoding peroxisomal lipid-
metabolizing enzymes, including ACO, bifunctional enzyme
and peroxisomal thiolase, and the fatty acid transporter
CD36 at a level comparable to that in wild-type mice,
expressing native mouse PPARα. This suggested that human
PPARα is functionally active. Upon treatment with Wy-
14,643, hPPARαTetOﬀ mice also had lower levels of fasting
serum total triglycerides similar to wild-type mice. However,
hPPARαTetOﬀ mice did not show any signiﬁcant hepatocel-
lular proliferation, nor did they have an induction of cell
cycle control genes, in contrast to Wy-14,643-treated wild-
type mice where a signiﬁcant increase in mRNAs encoding
PCNA, cMYC, cJUN, CDK1, CDK4, and several cyclins
was found after treatment with Wy-14,643. hPPARαTetOﬀ
mice were also found to be resistant to Wy-14,643-induced
hepatocarcinogenesis after 11 months of Wy-14,643 feeding
in contrast to a 100% incidence in the wild-type mouse
group [59].
Another transgenic mouse line with human PPARα was
generatedthat has the complete human PPARα gene on a
P1 phageartiﬁcial chromosome (PAC) genomic clone, intro-
duced onto the mouse PPARα-null background [60]. This
new line, designated hPPARαPAC, expresses human PPARα
not only in liver but also in kidney and heart. hPPARαPAC
mice exhibited responses similar to wild-type mice when
treated with fenoﬁbrate lowering of serum triglycerides and
inductionofPPARαtargetgenes’encodingenzymesinvolved
infattyacidmetabolism.TreatmentofhPPARαPAC micewith
fenoﬁbratedidnotcausesigniﬁcanthepatomegalyandhepa-
tocyte proliferation similar to hPPARαTetOﬀ mice, suggesting
that the resistance to the hepatocellular proliferation found
in the hPPARαTetOﬀ mice is not due to lack of expression of
the receptor in tissues other than liver.
Until now, there are no reports concerning the inter-
action between DEHP and hPPARαTetOﬀ or hPPARαPAC.
Recently, we have compared the transactivation of mouse
andhumanPPARαbyDEHPtreatmentsusingwild-typeand
hPPARαTetOﬀ mice (unpublished observation). A relatively10 PPAR Research
high dose of DEHP (5mmol/kg for 2 weeks) clearly activated
PPARα in liver of both genotyped mice, but the activation
was very little in hPPARαTetOﬀ mice from the standpoint of
the target gene expression as well as triglyceride levels in
plasma and liver. Human PPARα response to DEHP may
be weak when suﬃcient human PPARα is expressed in the
human liver. Thus, the use of the hPPARαTetOﬀ mouse model
is a very valuable means to solve the species diﬀerences in
the toxicity of peroxisome proliferators. The results from the
typical peroxisome proliferator (Wy-14643) may not always
be similar to those of DEHP; a study of each case is needed
using hPPARαTetOﬀ mouse model.
8. PROPOSED SCIENCE POLICY STATEMENTS
The International Agency for Research on Cancer down-
graded the level of potential health risks of DEHP from 2b
(possibly carcinogenic to humans) to 3 (not classiﬁable as
to carcinogenicity to humans) in 2000 [61]. In this report,
DEHP carcinogenesis via PPARα was considered not to
be relevant to humans because peroxisome proliferation
had not been documented either in human hepatocyte
cultures exposed to DEHP or in the liver of nonhuman
primates. This decision has been variously argued by several
scientists in the literature [50, 62, 63]. In contrast, the Japan
Society for Occupational Health has maintained the 2B class
of DEHP carcinogenicity because of the obvious rodent
carcinogenicity [64].
Although the US Environmental Protection Agency
(EPA) had classiﬁed the risk for DEHP carcinogenicity
as B2 (probable human carcinogen) in 1993, recently,
the expert panel of EPA report has provided the current
scientiﬁc understanding of the mode(s) of action of PPARα
agonist-induced tumors observed in rodent bioassays that
are associated with PPARα agonisms: liver tumors in rats
and mice as well as Leydig cell and pancreatic acinar cell
tumors in rats—all of which represent limited evidence [65].
Since the key events for the mode of action, which have
been causally related to liver tumor formation, include the
activation of PPARα, perturbation of cell proliferation and
apoptosis, selective clonal expansion, and the PPARα-related
key events included in the expression of peroxisomal genes
(e.g., palmitoyl CoA oxidase and acyl CoA oxidase) and
peroxisome proliferation (i.e., an increase in the number and
size of peroxisomes) are reliable markers. Additionally, the
evidence obtained from the ﬁndings that PPARa agonists
did not activate the receptor in human cell culture or
biopsy samples, and from epidemiological studies, shows
that humans are apparently refractory to the eﬀects of a
PPARα agonist. However, the EPA maintained the DEHP
carcinogenicity criterion.
In 2004, with regard to preclinical and clinical safety
assessments for PPAR agonists, the Food and Drug Adminis-
tration recommended that, due to the prevalence of positive
tumor ﬁndings of PPAR agonists, two-year carcinogenicity
studies on mice and rats are required [66].
AlthoughIARCchangedthecriterion forDEHP carcino-
genicity, other agencies did not because DEHP is a potential
rodentcarcinogenofliverandtheprecisemechanismhasnot
been yet understood, though DEHP is a potentially hepatic
c a r c i n o g e ni nr o d e n t s .
9. CONCLUSIONS
As mentioned above, some studies suggest the possibility of
DEHP tumorigenesis via a non-PPARα pathway although
DEHPalsoexertsadverseeﬀectsviaPPARα-dependentpath-
way. Since there are species diﬀerences regarding expression
levels, cellular context, and function of PPARα as well
as metabolism enzyme activity of DEHP, it is diﬃcult to
extrapolate the results from rodents to humans in terms of
risk. Recently, hPPARα mice have been developed, which
may help to solve these diﬀerences. Re-evaluation of the
risk of DEHP carcinogenicity may well be warranted if the
previous decisions were based on only PPARα-dependent
mechanisms.
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